UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 41

Sortiert nach

First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease

Alzheimer's & dementia : translational research & clinical interventions, 2016-09, Vol.2 (3), p.169-176

2016

Link zum Volltext

Verfügbarkeit prüfen

The definition of neuronopathic Gaucher disease

Journal of inherited metabolic disease, 2020-09, Vol.43 (5), p.1056-1059

2020

Link zum Volltext

Verfügbarkeit prüfen

Characterization of 3 Novel Tau Radiopharmaceuticals, 11C-RO-963, 11C-RO-643, and 18F-RO-948, in Healthy Controls and in Alzheimer Subjects

The Journal of nuclear medicine (1978), 2018-12, Vol.59 (12), p.1869-1876

2018

Link zum Volltext

Verfügbarkeit prüfen

Proof-of-Mechanism Study of the Phosphodiesterase 10 Inhibitor RG7203 in Patients With Schizophrenia and Negative Symptoms

Biological psychiatry global open science, 2021-06, Vol.1 (1), p.70-77

2021

Link zum Volltext

Verfügbarkeit prüfen

The antibody aducanumab reduces Aβ plaques in Alzheimer's disease

Nature (London), 2016-09, Vol.537 (7618), p.50-56

2016

Link zum Volltext

Verfügbarkeit prüfen

Amyloid PET Screening for Enrichment of Early-Stage Alzheimer Disease Clinical Trials: Experience in a Phase 1b Clinical Trial

Alzheimer disease and associated disorders, 2016-01, Vol.30 (1), p.1-7

2016

Link zum Volltext

Verfügbarkeit prüfen

Landscape of antibody immunotherapy for Alzheimer’s disease

Neurobiology of aging, 2016-03, Vol.39, p.S25-S26

2016

Link zum Volltext

Verfügbarkeit prüfen

Amyloid pet imaging: prime 1b study

Neurobiology of aging, 2016-03, Vol.39, p.S25-S25

2016

Link zum Volltext

Verfügbarkeit prüfen

Characterization of 3 Novel Tau Radiopharmaceuticals, ^sup 11^C-RO-963, ^sup 11^C-RO-643, and ^sup 18^F-RO-948, in Healthy Controls and in Alzheimer Subjects

The Journal of nuclear medicine (1978), 2018-12, Vol.59 (12), p.1869

2018

Link zum Volltext

Verfügbarkeit prüfen

Advances in active and passive immunotherapy for Alzheimer's disease

Neurobiology of aging, 2014-03, Vol.35, p.S10-S10

2014

Link zum Volltext

Verfügbarkeit prüfen

Characterization of 3 Novel Tau Radiopharmaceuticals, 11 C-RO-963, 11 C-RO-643, and 18 F-RO-948, in Healthy Controls and in Alzheimer Subjects

Journal of Nuclear Medicine, 2018-12, Vol.59 (12), p.1869-1876

2018

Link zum Volltext

Verfügbarkeit prüfen

Effects of Body Weight on Tolerability of Rivastigmine Transdermal Patch: A Post-hoc Analysis of a Double-blind Trial in Patients With Alzheimer Disease

Alzheimer disease and associated disorders, 2011, Vol.25 (1), p.58-62

2011

Link zum Volltext

Verfügbarkeit prüfen

Hoehn and Yahr Stage and Striatal Dat-SPECT Uptake Are Predictors of Parkinson's Disease Motor Progression

Frontiers in neuroscience, 2021-12, Vol.15, p.765765-765765

2021

Link zum Volltext

Verfügbarkeit prüfen

Addendum: The antibody aducanumab reduces A[beta] plaques in Alzheimer's disease

Nature (London), 2017-06, Vol.546 (7659), p.564

2017

Link zum Volltext

Verfügbarkeit prüfen

Addendum: The antibody aducanumab reduces Aβ plaques in Alzheimer's disease

Nature (London), 2017-06, Vol.546 (7659), p.564-564

2017

Link zum Volltext

Verfügbarkeit prüfen

O4‐04‐05: Aducanumab (BIIB037), an anti‐amyloid beta monoclonal antibody, in patients with prodromal or mild Alzheimer's disease: Interim results of a randomized, double‐blind, placebo‐controlled, phase 1b study

Alzheimer's & dementia, 2015-07, Vol.11 (7S_Part_6), p.P277-P277

2015

Link zum Volltext

Verfügbarkeit prüfen

CONCORDANCE OF QUANTITATIVE SUVR METHODS WITH VISUAL ASSESSMENT OF FLORBETAPIR PET SCREENING RESULTS

Alzheimer's & dementia, 2014-07, Vol.10 (4), p.P399-P399

2014

Link zum Volltext

Verfügbarkeit prüfen

P1‐252: CONCORDANCE OF QUANTITATIVE SUVR METHODS WITH VISUAL ASSESSMENT OF FLORBETAPIR PET SCREENING RESULTS

Alzheimer's & dementia, 2014-07, Vol.10 (4S_Part_10), p.P399-P399

2014

Link zum Volltext

Verfügbarkeit prüfen

O4‐07‐02: ENRICHMENT OF EARLY‐STAGE AD PATIENT RECRUITMENT TO A PHASE IB STUDY (221AD103) THROUGH AMYLOID PET SCREENING BY APOE ɛ4 STATUS

Alzheimer's & dementia, 2014-07, Vol.10 (4S_Part_4)

2014

Link zum Volltext

Verfügbarkeit prüfen

ENRICHMENT OF EARLY-STAGE AD PATIENT RECRUITMENT TO A PHASE IB STUDY (221AD103) THROUGH AMYLOID PET SCREENING BY APOE ɛ4 STATUS

Alzheimer's & dementia, 2014-07, Vol.10 (4), p.P263-P264

2014

Link zum Volltext

Verfügbarkeit prüfen

O4‐07‐02: ENRICHMENT OF EARLY‐STAGE AD PATIENT RECRUITMENT TO A PHASE IB STUDY (221AD103) THROUGH AMYLOID PET SCREENING BY APOE ɛ4 STATUS

Alzheimer's & dementia, 2014-07, Vol.10, p.P263-P264

2014

Link zum Volltext

Verfügbarkeit prüfen

ENRICHMENT OF EARLY-STAGE AD PATIENT RECRUITMENT TO A PHASE IB STUDY (221AD103) THROUGH AMYLOID PET SCREENING BY APOE ɛ4 STATUS

Alzheimer's & dementia, 2014, Vol.10 (4), p.P263-P264

2014

Link zum Volltext

Verfügbarkeit prüfen

The antibody aducanumab reduces A[beta] plaques in Alzheimer's disease

Nature (London), 2016-09, Vol.537 (7618), p.50

2016

Link zum Volltext

Verfügbarkeit prüfen

P3‐212: OPTIMIZED, FULLY‐AUTOMATED CLASSIFICATION OF AMYLOID‐POSITIVE SUBJECTS BASED ON [18F]FLORBETAPIR PET SCANS

Alzheimer's & dementia, 2014-07, Vol.10 (4S_Part_19), p.P708-P709

2014

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 41

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(39)
Mit Volltextzugriff
(35)

Publikationsform

Artikel
(41)

Sprache

Englisch
(41)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Neurology
(14)
Science & Technology
(10)
Life Sciences & Biomedicine
(9)
Humans
(6)
Female
(5)
Male
(5)
Aged
(4)
Alzheimer's Disease
(4)
Neurosciences & Neurology
(4)
Aged, 80 And Over
(3)
Alzheimer Disease - Drug Therapy
(3)
Internal Medicine
(3)
Medicine, Research & Experimental
(3)
Research & Experimental Medicine
(3)
Adolescent
(2)
Advertising Executives
(2)
Alzheimer Disease
(2)
Alzheimer Disease - Pathology
(2)
Animals
(2)
Antibodies, Monoclonal, Humanized - Therapeutic Use
(2)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease

The definition of neuronopathic Gaucher disease

Characterization of 3 Novel Tau Radiopharmaceuticals, 11C-RO-963, 11C-RO-643, and 18F-RO-948, in Healthy Controls and in Alzheimer Subjects

Proof-of-Mechanism Study of the Phosphodiesterase 10 Inhibitor RG7203 in Patients With Schizophrenia and Negative Symptoms

The antibody aducanumab reduces Aβ plaques in Alzheimer's disease

Amyloid PET Screening for Enrichment of Early-Stage Alzheimer Disease Clinical Trials: Experience in a Phase 1b Clinical Trial

Patients with autism spectrum disorders display reproducible functional connectivity alterations

Landscape of antibody immunotherapy for Alzheimer’s disease

Amyloid pet imaging: prime 1b study

Characterization of 3 Novel Tau Radiopharmaceuticals, ^sup 11^C-RO-963, ^sup 11^C-RO-643, and ^sup 18^F-RO-948, in Healthy Controls and in Alzheimer Subjects

Advances in active and passive immunotherapy for Alzheimer's disease

Characterization of 3 Novel Tau Radiopharmaceuticals, 11 C-RO-963, 11 C-RO-643, and 18 F-RO-948, in Healthy Controls and in Alzheimer Subjects

Effects of Body Weight on Tolerability of Rivastigmine Transdermal Patch: A Post-hoc Analysis of a Double-blind Trial in Patients With Alzheimer Disease

Hoehn and Yahr Stage and Striatal Dat-SPECT Uptake Are Predictors of Parkinson's Disease Motor Progression

Addendum: The antibody aducanumab reduces A[beta] plaques in Alzheimer's disease

Addendum: The antibody aducanumab reduces Aβ plaques in Alzheimer's disease

O4‐04‐05: Aducanumab (BIIB037), an anti‐amyloid beta monoclonal antibody, in patients with prodromal or mild Alzheimer's disease: Interim results of a randomized, double‐blind, placebo‐controlled, phase 1b study

CONCORDANCE OF QUANTITATIVE SUVR METHODS WITH VISUAL ASSESSMENT OF FLORBETAPIR PET SCREENING RESULTS

P1‐252: CONCORDANCE OF QUANTITATIVE SUVR METHODS WITH VISUAL ASSESSMENT OF FLORBETAPIR PET SCREENING RESULTS

O4‐07‐02: ENRICHMENT OF EARLY‐STAGE AD PATIENT RECRUITMENT TO A PHASE IB STUDY (221AD103) THROUGH AMYLOID PET SCREENING BY APOE ɛ4 STATUS

ENRICHMENT OF EARLY-STAGE AD PATIENT RECRUITMENT TO A PHASE IB STUDY (221AD103) THROUGH AMYLOID PET SCREENING BY APOE ɛ4 STATUS

O4‐07‐02: ENRICHMENT OF EARLY‐STAGE AD PATIENT RECRUITMENT TO A PHASE IB STUDY (221AD103) THROUGH AMYLOID PET SCREENING BY APOE ɛ4 STATUS

ENRICHMENT OF EARLY-STAGE AD PATIENT RECRUITMENT TO A PHASE IB STUDY (221AD103) THROUGH AMYLOID PET SCREENING BY APOE ɛ4 STATUS

The antibody aducanumab reduces A[beta] plaques in Alzheimer's disease

P3‐212: OPTIMIZED, FULLY‐AUTOMATED CLASSIFICATION OF AMYLOID‐POSITIVE SUBJECTS BASED ON [18F]FLORBETAPIR PET SCANS

Suchergebnisse filtern